Bulletin
Investor Alert

Lipocine Inc.

NAS: LPCN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 26, 2022, 7:57 p.m.

/zigman2/quotes/202742746/composite

$

0.44

Change

-0.0048 -1.08%

Volume

Volume 9,597

Quotes are delayed by 20 min

/zigman2/quotes/202742746/composite

Previous close

$ 0.50

$ 0.44

Change

-0.05 -10.41%

Day low

Day high

$0.43

$0.49

Open

52 week low

52 week high

$0.43

$1.89

Open

Jeffrey Arvin Fink

Jeffrey Arvin Fink is on the board of Progenitor, Inc., Lipocine, Inc. and Navigen, Inc. and Managing Director at Gambel Oaks Advisors LLC.

Mr. Fink previously was Partner at Dresdner Kleinwort Securities LLC, Head-Mergers & Acquisitions at Prudential Vector Healthcare Group and Head-Healthcare Investment Banking at Robert W. Baird & Co., Inc.

Mr. Fink received an MBA from the University of Michigan and an undergraduate degree from Kalamazoo College.

Transactions

Date Shares Transaction Value
12/16/2020 5,625   Derivative/Non-derivative trans. at $0 per share. 0
12/29/2017 938   Disposition at $3.47 per share. 3,255
12/29/2017 1,875   Derivative/Non-derivative trans. at $0 per share. 0

Officers and Executives

Dr. Mahesh V. Patel
Chairman, President, Chief Executive Officer & CFO
Dr. Anthony DelConte
Chief Medical Director
Dr. Nachiappan Chidambaram
Vice President-Product Development
Mr. John W. Higuchi
Director
Ms. Krista Fogarty
Chief Accounting Officer
Mr. Hans Vitzthum
Head-Investors Relation Contact
Dr. Jill M. Jene
Independent Director
Dr. Spyros Papapetropoulos
Independent Director
Dr. Richard Dana Ono
Independent Director
Mr. Jeffrey Arvin Fink
Independent Director
Link to MarketWatch's Slice.